“Cleveland Clinic spinoff company NeuroTherapia Inc. will start clinical trials of a new drug targeting inflammation of the brain that’s found in Alzheimer’s and other neurological diseases, according to a news release.

The U.S. Food and Drug Administration gave the company the go-ahead to begin its first in-human studies of the drug, NTRX-07, in an ascending dose study schedule to begin midsummer.

NeuroTherapia plans to follow this study, which will be in healthy volunteers, with another study in patients with Alzheimer’s disease to explore the safety of repeated dosing of NTRX-07 and to look for changes in inflammation, according to the release.”


Read on here.